| |  Online-Ressource |
|---|
| Verfasst von: | Haag, Georg Martin [VerfasserIn]  |
|---|
| | Zörnig, Inka [VerfasserIn] |
|---|
| | Hassel, Jessica C. [VerfasserIn] |
|---|
| | Halama, Niels [VerfasserIn] |
|---|
| | Dick, Julika [VerfasserIn] |
|---|
| | Lang, Nina [VerfasserIn] |
|---|
| | Podola, Lilli [VerfasserIn] |
|---|
| | Ziegelmeier, Claudia [VerfasserIn] |
|---|
| | Freitag, Angelika [VerfasserIn] |
|---|
| | Beckhove, Philipp [VerfasserIn] |
|---|
| | Enk, Alexander [VerfasserIn] |
|---|
| | Jäger, Dirk [VerfasserIn] |
|---|
| Titel: | Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1 |
|---|
| Verf.angabe: | G. M. Haag, I. Zoernig, J. C. Hassel, N. Halama, J. Dick, N. Lang, L. Podola, J. Funk, C. Ziegelmeier, S. Juenger, M. Bucur, L. Umansky, C. S. Falk, A. Freitag, I. Karapanagiotou-Schenkel, P. Beckhove, A. Enk, D. Jaeger |
|---|
| E-Jahr: | 2018 |
|---|
| Jahr: | 5 January 2018 |
|---|
| Umfang: | 8 S. |
|---|
| Fussnoten: | Gesehen am 15.08.2019 |
|---|
| Titel Quelle: | Enthalten in: European journal of cancer |
|---|
| Ort Quelle: | Amsterdam [u.a.] : Elsevier, 1992 |
|---|
| Jahr Quelle: | 2018 |
|---|
| Band/Heft Quelle: | 90(2018), Seite 122-129 |
|---|
| ISSN Quelle: | 1879-0852 |
|---|
| Abstract: | Background - Immune checkpoint therapy has dramatically changed treatment options in patients with metastatic melanoma. However, a relevant part of patients still does not respond to treatment. Data regarding the prognostic or predictive significance of preexisting immune responses against tumour antigens are conflicting. Retrospective data suggested a higher clinical benefit of ipilimumab in melanoma patients with preexisting NY-ESO-1-specific immunity. - Patients and methods - Twenty-five patients with previously untreated or treated metastatic melanoma and preexisting humoural immune response against NY-ESO-1 received ipilimumab at a dose of 10 mg/kg in week 1, 4, 7, 10 followed by 3-month maintenance treatment for a maximum of 48 weeks. Primary endpoint was the disease control rate (irCR, irPR or irSD) according to immune-related response criteria (irRC). Secondary endpoints included the disease control rate according to RECIST criteria, progression-free survival and overall survival (OS). Humoural and cellular immune responses against NY-ESO-1 were analysed from blood samples. - Results - Disease control rate according to irRC was 52%, irPR was observed in 36% of patients. Progression-free survival according to irRC was 7.8 months, according to RECIST criteria it was 2.9 months. Median OS was 22.7 months; the corresponding 1-year survival rate was 66.8%. Treatment-related grade 3 AEs occurred in 36% with no grade 4-5 AEs. No clear association was found between the presence of NY-ESO-1-specific cellular or humoural immune responses and clinical activity. - Conclusion - Ipilimumab demonstrated clinically relevant activity within this biomarker-defined population. NY-ESO-1 positivity, as a surrogate for a preexisting immune response against tumour antigens, might help identifying patients with a superior outcome from immune checkpoint blockade. Clinical trial information: NCT01216696 |
|---|
| DOI: | doi:10.1016/j.ejca.2017.12.001 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1016/j.ejca.2017.12.001 |
|---|
| | Volltext: http://www.sciencedirect.com/science/article/pii/S0959804917314570 |
|---|
| | DOI: https://doi.org/10.1016/j.ejca.2017.12.001 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Cancer/testis antigen |
|---|
| | Immunotherapy |
|---|
| | Ipilimumab |
|---|
| | Melanoma |
|---|
| | NY-ESO-1 |
|---|
| K10plus-PPN: | 167144812X |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1 / Haag, Georg Martin [VerfasserIn]; 5 January 2018 (Online-Ressource)
